Teva Pharmaceutical Industries Ltd.

Major Shareholding Notification • Mar 1, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person Conway Vikki L.	2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited TEVA	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner
(Last) (First) (Middle) C/O Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St.,	3. Date of Earliest Transaction (Month/Day/Year) 02/28/2024	Officer (give title below) Other (specify below) See "Remarks"
(Street) Tel Aviv, L3 6944020	4. If Amendment, Date Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person
(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security	2. Transaction	2A. Deemed	3. Transaction		4. Securities Acquired			5. Amount of Securities Beneficially		7. Nature
(Instr. 3)	Date	Execution Date, if Code			(A) or Disposed of (D)			Owned Following Reported	Ownership of Indirect
	(Month/Day/Year) any		(Instr. 8)		(Instr. 3, 4 and 5)			Transaction(s)	l Form:	Beneficial
		(Month/Day/Year)						(Instr. 3 and 4)	Direct (D) Ownership
						(A)			or Indirect (Instr. 4)
						01			(1)
			Code		Amount	(D)	Price		(Instr. 4)
Ordinary Shares (1)	02/28/2024		M		4.294	ત	(2)	4.294	D

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

02/28/2024 Ordinary Shares (1)		1					2,928
-----------------------------------	--	---	--	--	--	--	-------	--	--

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

				( e.g. , puts, calls, warrants, options, convertible securities)
--	--	--	--	------------------------------------------------------------------	--

1. Title of	2	3. Transaction	3A. Deemed	4.		5. Number		6. Date Exercisable		7. Title and Amount			8. Price of 9. Number of	10.	11. Nature
Derivative	Conversion Date		Execution Date, if Transaction of					and Expiration Date of Underlying				Derivative Derivative	Ownership of Indirect
Security		or Exercise (Month/Day/Year)	any	Code			Derivative	(Month/Day/Year)		Securities		Security	Securities	Form of	Beneficial
(Instr. 3)	Price of		(Month/Day/Year) (Instr. 8)				Securities			(Instr. 3 and 4)		(Instr. 5)	Beneficially	Derivative Ownership
	Derivative					Acquired							Owned	Security:	(Instr. 4)
	Security				(A) or						Following	Direct (D)
						Disposed							Reported	or Indirect
					of (D)								Transaction(s) (I)
					(Instr. 3, 4,							(Instr. 4)	(Instr. 4)
						and 5)
											Amount
											Or
								Date	Expiration	Title	Number
								Exercisable Date			of
				Code		(A	(D)				Shares
Restricted
Share	(2)	02/28/2024		M			4,294	(6)	(6)	Ordinary	4,294	\$ 0	0	D
Units										Shares

Explanation of Responses:

• 1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
• 1. Each restricted share unitingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Committee, the cash value of one ordinary share.
• 1. The transaction reported in this Form 4 was effected pursuant to a Rule 105-1 trading plan adopted by the reporting person on November 21, 2023.
• 1. Represents the number of shares required to be sold by the reason to conection with the vesting of the resting of the resting of the restricted share units listed in Table II.
• 1. The price in Column 4 is a weighted avere sold in multiple transactions at prices ranging from \$1.0 to \$1.19, inclusive. The reporting person undertakes to provide, upon request by the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
• 1. Restricted share units were granted on February 28, 2020, with 4,294 vested on February 28, 2024.

Remarks:

Acting Head of Global Human Resources

Signatures

/s/ Dov Bergwerk as attorney-in-fact for Vikki L. Conway 03/01/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly.

• * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
• ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 18f(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information in this form are not required to respond unless the form displays a currently valid OMB Number.